Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma
Public ClinicalTrials.gov record NCT03361748. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Multicenter Study to Determine the Efficacy and Safety of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is an open label, single-arm, multicenter, Phase 2 study to evaluate the efficacy and safety of bb2121 in subjects with relapsed and refractory multiple myeloma. A leukapheresis procedure will be performed to manufacture bb2121 chimeric antigen receptor (CAR) modified T cells. Prior to bb2121 infusion subjects will receive lymphodepleting therapy with fludarabine and cyclophosphamide.
Study identification
- NCT ID
- NCT03361748
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 149 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 13, 2017 (Actual)
- Primary completion
- Dec 20, 2023 (Actual)
- Completion
- Dec 20, 2023 (Actual)
- Last update posted
- May 23, 2025
2017 – 2023
United States locations
- U.S. sites
- 18
- U.S. states
- 8
- U.S. cities
- 8
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Local Institution - 108 | San Francisco | California | 94143 | — |
| University of California - San Francisco | San Francisco | California | 94143 | — |
| Emory University | Atlanta | Georgia | 30322 | — |
| Local Institution - 103 | Atlanta | Georgia | 30322 | — |
| Local Institution - 107 | Boston | Massachusetts | 02114 | — |
| Dana Farber Cancer Institute | Boston | Massachusetts | 02115 | — |
| Massachusetts General Hospital | Boston | Massachusetts | 02214 | — |
| Local Institution - 106 | Boston | Massachusetts | 02215 | — |
| Local Institution - 105 | Rochester | Minnesota | 55905 | — |
| Mayo Clinic | Rochester | Minnesota | 55905 | — |
| Hackensack University Medical Center | Hackensack | New Jersey | 07601 | — |
| Local Institution - 102 | Hackensack | New Jersey | 07601 | — |
| Local Institution - 109 | New York | New York | 10029 | — |
| Mt. Sinai Medical Center | New York | New York | 10029 | — |
| Local Institution - 101 | Nashville | Tennessee | 37203 | — |
| Sarah Cannon Research Institute | Nashville | Tennessee | 37203 | — |
| Local Institution - 104 | Dallas | Texas | 75390 | — |
| University of Texas Southwestern Medical Center | Dallas | Texas | 75390 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 30 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03361748, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 23, 2025 · Synced Oct 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03361748 live on ClinicalTrials.gov.